Pediatric Immunization

Misinformation about measles and the MMR vaccine has reached the majority of US adults and parents; most believe the vaccine is safe but many are still unconvinced.

Here, the 5 key signs and symptoms that characterize measles in the order of appearance.

Clesrovimab, if approved, would be the only immunization for both healthy and at risk infants using the same dose. FDA set A PDUFA date of June 2025.

Moderna paused clinical research on the pediatric shot indefinitely in September after reports in July of severe adverse reactions in infants aged 5 to 8 months.

HPV series initiation and completion was lower among adolescents seen at public vs private care settings and so was clinician guidance on vaccination in a new study.

A new study shows that higher vaccination rates were associated with a decrease in the prevalence of parent-reported asthma symptoms in children.

In a new real-world study, Sanofi and AstraZeneca’s nirsevimab-alip (Beyfortus) demonstrated high efficacy against respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD).

The FDA expects to take action on the GSK BLA for its pentavalent MenB vaccine by February 14, 2025.

Measles cases are edging up in the US again as MMR vaccination rates continue to decline. Have parents forgotten the Ohio outbreak of 2022? Have you? Find out, here.

Your daily dose of the clinical news you may have missed.

Findings support current CDC recommendations that all infants should be protected by maternal RSV vaccination or infant receipt of nirsevimab.

Just when the new monovalent COVID-19 vaccines were available in Sept 2023, a new variant emerged. Did the CDC get it right? What do you know about the monovalent VE?

According to a new CDC report, 38.6% of children aged 9-17 years received ≥1 doses of the HPV vaccine in 2022.

Should you pregnant patient get the new RSV vaccine at the appropriate time during gestation or wait and have the baby receive Beyfortus after birth?

Measles cases are reported in 6 states, which is not a surprise to one pediatrician who points to the ongoing consequences of falling vaccination rates.

Your daily dose of the clinical news you may have missed.

Vaccination against SARS-CoV-2 was associated with reduced risk of long COVID for at least 12 months in children and adolescents in a new large retrospective study.

Click through a short slideshow review of the available COVID-19 vaccines for adults and children and of the long COVID symptoms to watch for in all your patients.

Tell us what features you would find most valuable in a rapid point-of-care test for simultaneous detection of respiratory viruses in pediatric patients.

The best defense against long COVID remains COVID-19 vaccination. This short slide show highlights long COVID symptoms and CDC vaccination recommendations.

Experts discuss the efficacy of the latest vaccines against currently circulating strains of COVID-19, commenting on how long immunity lasts from these vaccines.

Drs Tina Q Tan and Rodney Rohde review the importance of vaccinating against COVID-19 to prevent long COVID, as well as highlight the current vaccination recommendations.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Misinformation about COVID-19 vaccines may have eroded parents' trust in vaccination for their children, according to authors of new research.

Nonmedical exemptions from required school vaccinations accounted for more than 90% of the increase, according to the published data.

The world's first maternal vaccine against RSV in neonates and infants was approved in August. This brief slide show highlights the clinical trials that made history.

Collaboration among care team members is a key ingredient to effective support for children with disabilities and this specialist says her welcome mat is out for her neighbors.

The Pfizer product is the first vaccine indicated to prevent the 5 most common serogroups causing meningococcal disease in adolescents and young adults.

IDWeek 2023. Nirsevimab efficacy was significant across infant subgroups in preventing hospitalization for RSV-LRTI during a first RSV season.